Pemphigus

Desmoglein 3 chimeric autoantibody receptor T cells (DSG3-CAART)

DSG3-CAART has received fast track designation from the US Food and Drug Administration for the treatment of mucosal pemphigus vulgaris. DSG3-CAART improves healing of mucosal blisters by targeting and killing the B cells that express pathogenic autoantibodies, while preserving the healthy B cells critical to immune function. A phase 1 trial is underway to establish the maximum tolerated dose and the incidence of adverse events.[49]US Nation Library of Medicine. Open-label Study to Determine the Maximum Tolerated Dose of DSG3-CAART in Mucosal-dominant PV Patients (mPV). Jan 2021 [internet publication]. https://clinicaltrials.gov/ct2/show/NCT04422912